Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dimethyl Fumarate for Mild Cognitive Impairment and Alzheimer’s Disease
2024-517214-16-00Phase 2Authorised
- Sponsor
- Medical University of Lodz
- Start
- Nov 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Alzheimer's disease (AD) and mild cognitive impairment due to Alzheimer's disease comparing Dimethyl fumarate with Placebo (2 arms). Primary endpoint: Change in cognitive performance (RBANS). Planned start Nov 2024; status: authorised.
02
Drugs
dimethyl fumarate
03
Conditions
Alzheimer's disease (AD)mild cognitive impairment due to Alzheimer's disease
Beyond the preview
Go deeper on 2024-517214-16-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-517214-16-00.